MedGene Therapeutics, Inc.

MedGene Therapeutics is focused on developing ACT treatments (PMBC derived tumor-reactive T cells-Natural Unmodified CD8+ lymphocytes) for two cancers—MSTS (metastatic soft tissue sarcoma) and MFTC (metastatic follicular thyroid cancer)—using NIH patented technology with Worldwide Exclusive License... Read more